InsiderDB

SEC EDGAR · Company announcement

ALDX: Other company developments

Filed 8-K for an event or period dated 2026-11-09. Other company developments.

Follow ALDX
Became public
Nov 9, 2026, 4:02 PM EST
Event / period date
Nov 9, 2026
Collected
Nov 17, 2026, 5:56 PM EST

Why this is connected

This filing identifies Aldeyra Therapeutics, Inc. as the issuer of the security. The company's SEC identifier connects it to ALDX.

Source evidence

Read the source excerpt or record
Item 8.01. Other Events. On November 9, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) announced that the Company has formally requested that the Division of Ophthalmology (the “DO”) of the U.S. Food and Drug Administration (the “FDA”) submit a review jurisdiction request to the FDA’s Office of New Drugs (the “OND”) recommending that review of the Company’s Investigational New Drug application (the “IND”) for ADX-2191 for the treatment of primary vitreoretinal lymphoma (“PVRL”) be transferred to the FDA’s Division of Hematologic Malignancies 2 (“DHM2”). Aldeyra made this request because lymphoma reviews are typically conducted by DHM2, which maintains expertise in local and systemic manifestations of hematogenous cancers. In connection with this request, Aldeyra notified the FDA that it had withdrawn the Special Protocol Assessment (the “SPA”) protocol for ADX-2191 for the treatment of PVRL, which the DO had previously reviewed and agreed to. The submission of the review jurisdiction request is within the DO’s control, and any decision on the request is within the FDA’s discretion. While the jurisdictional request is pending, the Company does not expect to initiate the clinical trial contemplated by the SPA. The following risk factor supplements, and should be read together with, the risk factors previously disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026; June 30, 2026; and September 30, 2026. We have requested that review of our Investigational New Drug application (the “IND”) for ADX-2191 in primary vitreoretinal lymphoma be transferred to a different U.S. Food and Drug Administration (the “FDA”) review division,

Price change after we could observe it

+7.54% ALDX

Adjusted closing prices from Nov 18, 2026 to Nov 19, 2026. SPY changed -1.40% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.